292 related articles for article (PubMed ID: 34269079)
1. Operationalizing the Use of Biofabricated Tissue Models as Preclinical Screening Platforms for Drug Discovery and Development.
Jung O; Song MJ; Ferrer M
SLAS Discov; 2021 Oct; 26(9):1164-1176. PubMed ID: 34269079
[TBL] [Abstract][Full Text] [Related]
2. Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery.
Ekert JE; Deakyne J; Pribul-Allen P; Terry R; Schofield C; Jeong CG; Storey J; Mohamet L; Francis J; Naidoo A; Amador A; Klein JL; Rowan W
SLAS Discov; 2020 Dec; 25(10):1174-1190. PubMed ID: 32495689
[TBL] [Abstract][Full Text] [Related]
3. A biofabricated vascularized skin model of atopic dermatitis for preclinical studies.
Liu X; Michael S; Bharti K; Ferrer M; Song MJ
Biofabrication; 2020 Apr; 12(3):035002. PubMed ID: 32059197
[TBL] [Abstract][Full Text] [Related]
4. 3D bioprinting for drug discovery and development in pharmaceutics.
Peng W; Datta P; Ayan B; Ozbolat V; Sosnoski D; Ozbolat IT
Acta Biomater; 2017 Jul; 57():26-46. PubMed ID: 28501712
[TBL] [Abstract][Full Text] [Related]
5. 3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing.
Boutin ME; Hampton C; Quinn R; Ferrer M; Song MJ
Adv Exp Med Biol; 2019; 1186():171-193. PubMed ID: 31654390
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications.
Xie R; Pal V; Yu Y; Lu X; Gao M; Liang S; Huang M; Peng W; Ozbolat IT
Biomaterials; 2024 Jan; 304():122408. PubMed ID: 38041911
[TBL] [Abstract][Full Text] [Related]
7. Engineered tissues and strategies to overcome challenges in drug development.
Khalil AS; Jaenisch R; Mooney DJ
Adv Drug Deliv Rev; 2020; 158():116-139. PubMed ID: 32987094
[TBL] [Abstract][Full Text] [Related]
8. Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation.
Portillo-Lara R; Spencer AR; Walker BW; Shirzaei Sani E; Annabi N
Biomaterials; 2019 Apr; 198():78-94. PubMed ID: 30201502
[TBL] [Abstract][Full Text] [Related]
9. Translational in vitro research: integrating 3D drug discovery and development processes into the drug development pipeline.
Kelm JM; Lal-Nag M; Sittampalam GS; Ferrer M
Drug Discov Today; 2019 Jan; 24(1):26-30. PubMed ID: 30071313
[TBL] [Abstract][Full Text] [Related]
10. Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers.
Amirghasemi F; Adjei-Sowah E; Pockaj BA; Nikkhah M
Ann Biomed Eng; 2021 Aug; 49(8):1943-1972. PubMed ID: 33403451
[TBL] [Abstract][Full Text] [Related]
11. 3D-bioprinted all-inclusive bioanalytical platforms for cell studies.
Mazrouei R; Velasco V; Esfandyarpour R
Sci Rep; 2020 Sep; 10(1):14669. PubMed ID: 32887912
[TBL] [Abstract][Full Text] [Related]
12. 3D cell cultures toward quantitative high-throughput drug screening.
Wang Y; Jeon H
Trends Pharmacol Sci; 2022 Jul; 43(7):569-581. PubMed ID: 35504760
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation.
Struzyna LA; Watt ML
Mol Pharmacol; 2021 Apr; 99(4):256-265. PubMed ID: 33547249
[TBL] [Abstract][Full Text] [Related]
14. Cell spheroids as a versatile research platform: formation mechanisms, high throughput production, characterization and applications.
Decarli MC; Amaral R; Santos DPD; Tofani LB; Katayama E; Rezende RA; Silva JVLD; Swiech K; Suazo CAT; Mota C; Moroni L; Moraes ÂM
Biofabrication; 2021 Apr; 13(3):. PubMed ID: 33592595
[TBL] [Abstract][Full Text] [Related]
15. 3D in vitro tissue models and their potential for drug screening.
Kimlin L; Kassis J; Virador V
Expert Opin Drug Discov; 2013 Dec; 8(12):1455-66. PubMed ID: 24144315
[TBL] [Abstract][Full Text] [Related]
16. 3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis.
Booij TH; Price LS; Danen EHJ
SLAS Discov; 2019 Jul; 24(6):615-627. PubMed ID: 30817892
[TBL] [Abstract][Full Text] [Related]
17. A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery.
Joslin J; Gilligan J; Anderson P; Garcia C; Sharif O; Hampton J; Cohen S; King M; Zhou B; Jiang S; Trussell C; Dunn R; Fathman JW; Snead JL; Boitano AE; Nguyen T; Conner M; Cooke M; Harris J; Ainscow E; Zhou Y; Shaw C; Sipes D; Mainquist J; Lesley S
SLAS Discov; 2018 Aug; 23(7):697-707. PubMed ID: 29843542
[TBL] [Abstract][Full Text] [Related]
18. Complex In Vitro Model Characterization for Context of Use in Toxicologic Pathology: Use Cases by Collaborative Teams of Biologists, Bioengineers, and Pathologists.
Stokar-Regenscheit N; Bell L; Berridge B; Rudmann D; Tagle D; Hargrove-Grimes P; Schaudien D; Hahn K; Kühnlenz J; Ashton RS; Tseng M; Reichelt M; Laing ST; Kiyota T; Chamanza R; Sura R; Tomlinson L
Toxicol Pathol; 2024 Jun; ():1926233241253811. PubMed ID: 38888280
[TBL] [Abstract][Full Text] [Related]
19. Microengineering methods for cell-based microarrays and high-throughput drug-screening applications.
Xu F; Wu J; Wang S; Durmus NG; Gurkan UA; Demirci U
Biofabrication; 2011 Sep; 3(3):034101. PubMed ID: 21725152
[TBL] [Abstract][Full Text] [Related]
20. Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future.
Devarasetty M; Mazzocchi AR; Skardal A
BioDrugs; 2018 Feb; 32(1):53-68. PubMed ID: 29383499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
